STIM · Neuronetics, Inc.
$1.83
-0.04 (-2.14%)
At close · Jul 29
Going-concern doubt
— flagged May 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company currently projects trailing twelve-month revenue for the period ended March 31, 2027 to be below the minimum required revenue for that period as stated in the credit facility agreement. Should the Company not be able to meet its March 31, 2027 minimum revenue covenant, the lender may at that time and at its discretion, call the credit facility. Should the lender call the facility, the Company is not projected to have the liquidity required to meet its requirement to pay off the loan. Therefore, substantial doubt exists about the Company's ability to continue as a going concern. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period.”View the 10-Q filed May 5, 2026
Market Cap
$130.13M
Shares
69.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.87
Open$1.81
Day$1.77–1.87
52W$0.80–4.85
Avg vol 30d2.0M
Short int9.4M · 13.5% float · 7.8d
Short vol36%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
+28%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
26%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+38%
trailing
6-month return
+3%
trailing
YTD return
+36%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
16 of 98 funds reported for Jun 30 · net -13.7K sh shares · +2 new
Insider flow
Accumulating
Net +$815.8K over 90 days · 0% sells
Short interest
Rising
13.47% of float · ▲ +22.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
137%
expanding
EPS growth
+57%
Y/Y
Balance sheet
$50.8M
net debt
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
10.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Total revenue
· full year 2026
Maintained
$160M – $166M
prior FY $149.16M
midpoint +9.3% Y/Y
Gross margin
· full year 2026
Maintained
47% – 49%
Cash flow from operations
· full year 2026
Maintained
$-17M – $-13M
Guided vs delivered
· last 1 settled
Revenue
first quarter 2026
guided $33M – $35M
$34.45M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
16 of 98 funds reported for Jun 30 · net -13.7K sh shares · +2 new
Insider flow
Accumulating
Net +$815.8K over 90 days · 0% sells
Short interest
Rising
13.47% of float · ▲ +22.0% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 26%
52-wk high $5
vs 200-day avg +11%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| NeuroStar systems shipped | 34 | Q1 2026 | — |
|
|
|||
| operating cash flow | $0.9M | fourth quarter 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STIM
this stock
Neuronetics, Inc.
|
$130.13M | +35.5% | +30.5% | — | 13.5% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | -1.1% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.8% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.46B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STIM | -0.5% | +37.5% | +2.8% | +43.9% | +35.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +0.5% | +37.5% | -4.7% | +44.6% | +26.9% |